about
The Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors-Is Pharmacogenetics the Key?Polymorphic expression of UDP-glucuronosyltransferase UGTlA gene in human colorectal cancerCytochrome P450 CYP1A1: wider roles in cancer progression and prevention.Validation of an HPLC assay for determination of Telazol in pregnant pigs: application to placental transfer studyEffects of Prenatal Social Stress and Maternal Dietary Fatty Acid Ratio on Infant Temperament: Does Race Matter?Expression of UDP-glucuronosyltransferase 1A4 in human placenta at term.Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy.Human placental glutathione S-transferase activity and polycyclic aromatic hydrocarbon DNA adducts as biomarkers for environmental oxidative stress in placentas from pregnant women living in radioactivity- and chemically-polluted regions.Effects of gestational age and surface modification on materno-fetal transfer of nanoparticles in murine pregnancy.BCRP/ABCG2 in the placenta: expression, function and regulation.Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes.Drug transporters in the human blood-placental barrier.Developmental expression of drug metabolizing enzymes and transporter proteins in human placenta and fetal tissues.Oral hypoglycemic therapy: understanding the mechanisms of transplacental transfer.Introductory pharmacology for clinical practice.Current toxicological aspects on drug and chemical transport and metabolism across the human placental barrier.Are monoclonal antibodies a safe treatment for cancer during pregnancy?Nuclear receptors in regulation of biotransformation enzymes and drug transporters in the placental barrier.Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment.Placenta-on-a-chip: a novel platform to study the biology of the human placentaMultidrug resistance phosphoglycoprotein (ABCB1) expression in the guinea pig placenta: developmental changes and regulation by betamethasone.Does anthracycline-based chemotherapy in pregnant women with cancer offer safe cardiac and neurodevelopmental outcomes for the developing fetus?Biocompatibility assessment of titanium dioxide nanoparticles in mice fetoplacental unit.Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model I: Insights into Factors that Determine Fetal Drug Exposure through Simulations and Sensitivity Analyses.Associations among prenatal stress, maternal antioxidant intakes in pregnancy, and child temperament at age 30 months.
P2860
Q26741187-723B15D0-26CA-493D-8271-370DDBAC2C5DQ28487071-E5BB6BB1-A9CC-46D2-9A26-A13E6F406E74Q33468680-697CEFA5-B8D9-4BAF-8CB6-BFD026920A0AQ33594046-E552DE02-C3E8-42F7-873C-A70CFD7E53FDQ34342899-F35BB335-C62E-461A-AC31-A4E41A499DD5Q34557203-4E9A30B9-24C5-43AB-BB36-BFBC418BEBB4Q35557216-DF247CEC-1788-47ED-BE01-80EF140D74FAQ36330609-60AB34C7-CE68-4435-A316-1692E5CB39F6Q36393401-5D014029-E6D9-4D8A-982F-AE5971AE425BQ36593505-6EFFB97D-F4E6-48A3-B60D-13CEB5194128Q37272782-38284F2E-4BFD-4040-A56F-859A935C8DC6Q37395889-E9E83BC3-08DC-4A15-A331-90C64B3203EAQ37604379-45A10DC0-4CED-4E53-8EDF-61E8A8AA4041Q37671834-EC5477E5-2A40-40D5-A056-6927F97D16F2Q37871036-78AB54DE-58F6-4CC6-9819-73104EDAFA0BQ38025182-5EF91F1E-262F-483B-8AE4-55FC80248ADCQ38119550-8DA4AA1E-E35C-4784-9FA9-7A94D3A04C1BQ38135859-340D15F4-D6A5-4CD1-A580-CD8DEBE7822CQ38681424-8AD32C31-E394-4BC6-9031-F33AB37D75E2Q41668656-1A92C24D-DD90-4E5A-9926-78D013C12339Q43236348-1EF2B9F0-B1C2-4170-90AD-33E8337ACF02Q47164600-4808A513-A5B8-4FF1-BCE2-BC912709CF17Q47700745-1CE5FC0F-13BF-4836-A111-7172C8705EEEQ50597914-8D88E4D9-4A74-46F7-9091-18487B249509Q53195347-D32BB507-FF73-40FE-99BF-A014610322E3
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The fate and effects of xenobiotics in human placenta.
@en
type
label
The fate and effects of xenobiotics in human placenta.
@en
prefLabel
The fate and effects of xenobiotics in human placenta.
@en
P2093
P2860
P356
P1476
The fate and effects of xenobiotics in human placenta.
@en
P2093
Kirsi Vähäkangas
Markku Pasanen
Päivi Myllynen
P2860
P304
P356
10.1517/17425255.3.3.331
P407
P577
2007-06-01T00:00:00Z